Optos plc
Optos plc (LSE: OPTS), the leading medical retinal imaging company, today announces it has commenced first shipments of California, the second device from its next generation ultra-widefield (UWF™) imaging platform.
California is a compact table-top ultra-widefield retinal imaging device providing greater imaging functionality and is targeted at the ophthalmology market. California introduces the Company’s newest imaging modality; indocyanine green angiography (ICG) while maintaining all current colour imaging modalities, autofluorescence (AF) and fluorescein angiography (FA). ICG is used for imaging the choroidal vasculature which is important for the diagnosis, management and treatment of certain conditions such as neovascular age-related macular degeneration (AMD) and disorders with choroidal neovascular membranes.
In addition to ICG retinal imaging, the California has several software and hardware enhancements, including the new OptosAdvance software platform with advanced tools and an easier procedure workflow. New proprietary optical hardware allows resolution to be optimized and maintained throughout the scan of the retina resulting in more clarity in the far periphery. California also incorporates ProView™, which enhances image registration for tracking retinal disease development over time and comparison of images across all retinal image modalities. This functionality removes systematic image variations providing an accurate representation of anatomical features in the retina.
Roy Davis, CEO of Optos, said: “We have begun shipments of our California devices as planned, demonstrating a tremendous company-wide achievement. We have utilised the latest design, manufacturing and software technologies in California and continued our investment in clinical research to support this product launch. The addition of ICG in our newest UWF device provides retinal specialists and ophthalmologists with more imaging tools allowing them to see and treat retinal pathology more effectively. California further supports our entry into the ophthalmology segment and aspiration to make optomap® images a standard of care in this market.”
An early user of California, SriniVas R. Sadda, MD Doheny Eye Institute, added: “One of the great advantages of the Optos system has been the ability to capture the largest field of view in one image. The reality is that we didn’t know until we had ultra-widefield just how much disease was out in the far periphery. With the introduction of California, we have all of the current image modalities with the added benefit of ICG angiography imaging. ICG is going to be huge because it is an important component in treating difficult disease such as uveitis. I’m particularly excited about the new improvements to the optical system that further enhance visualisation of the inferior and superior periphery.”